Effects of Imidazoline and Non-Imidazoline α-Adrenergic Agents on Rabbit Platelet Aggregation

Pharmacology

Volumn 91, Issue 3-4, 2013, Pages 135-144

  Yokota, Shin Ichi ^a   Hikasa, Yoshiaki ^a   Mizushima, Hitomi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Adrenergic agents; Adrenoceptors; Catecholamines; Imidazoline; Platelet aggregation

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTAZOLINE; APRACLONIDINE; ATIPAMEZOLE; CLONIDINE; DETOMIDINE; IDAZOXAN; IMIDAZOLINE DERIVATIVE; MEDETOMIDINE; METHOXAMINE; NAPHAZOLINE; NORADRENALIN; OXYMETAZOLINE; PHENOXYBENZAMINE; PHENTOLAMINE; PRAZOSIN; TOLAZOLINE; XYLAZINE; YOHIMBINE; ADENOSINE DIPHOSPHATE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; COLLAGEN; IMIDAZOLINE; IMIDAZOLINE RECEPTOR; RADIOLIGAND; THROMBOCYTE RECEPTOR;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; ADULT; ANIMAL EXPERIMENT; BINDING ASSAY; CONTROLLED STUDY; DRUG POTENCY; THROMBOCYTE MEMBRANE; TURBIDIMETRY;

ADENOSINE DIPHOSPHATE; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; EPINEPHRINE; IMIDAZOLES; IMIDAZOLINE RECEPTORS; IMIDAZOLINES; MALE; NOREPINEPHRINE; PLATELET AGGREGATION; RABBITS;

EID: 84873034932     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000346269     Document Type: Article

References (49)

1. Sinakos Z, Caen JP: Platelet aggregation in mammalians (human, rat, rabbit, guinea-pig, horse, dog): a comparative study. Thromb Diath Haemorrh 1969; 17: 99-111
2. Kerry R, Scrutton MC, Wallis RB: Mammalian platelet adrenoceptors. Br J Pharmacol 1984; 81: 91-102
3. Naselsky DP, Ashton D, Ruffolo RR Jr, Hieble JP: Rabbit alpha2-adrenoceptors: both platelets and adipocytes have α 2A -pharmacology. J Pharmacol Exp Ther 2001; 298: 219-225
4. Grant JA, Scrutton MC: Novel α2-adrenoreceptors primarily responsible for inducing human platelet aggregation. Nature 1979; 277: 659-661
5. Hsu CY, Knapp DR, Halushka PV: The effects of alpha adrenergic agents on human platelet aggregation. J Pharmacol Exp Ther 1979; 208: 366-370
6. Lasch P, Jakobs KH: Agonistic and antagonistic effects of various alpha-adrenergic agonists in human platelets. Naunyn Schmiedebergs Arch Pharmacol 1979; 306: 119-125
7. Pinthong D, Songsermsakul P, Rattanachamnong P, Kendall DA: The effects of imidazoline agents on the aggregation of human platelets. J Pharm Pharmacol 2004; 56: 213- 220
8. Motulsky HJ, Shattil SJ, Insel PA: Characterization of α 2 -adrenergic receptors on human platelets using 3 Hyohimbine. Biochem Biophys Res Commun 1980; 97: 1562-1570
9. Shattil SJ, McDonough M, Turnbull J, Insel PA: Characterization of alpha-adrenergic receptors in human platelets using 3 Hclonidine. Mol Pharmacol 1981; 19: 179-183
10. Motulsky HJ, Insel PA: 3 HDihydroergocryptine binding to alpha-adrenergic receptors of human platelets: a reassessment using the selective radioligands 3 Hprazosin, 3 H yohimbine, and 3 Hrauwolscine. Biochem Pharmacol 1982; 31: 2591-2597
11. Lanza F, Cazenave JP: Studies of α 2 -adrenergic receptors of intact and functional washed human platelets by binding of 3 H-dihydroergocryptine and 3 H-yohimbine - correlation of H-yohimbine binding with the potentiation by adrenaline of ADP-induced aggregation. Thromb Haemost 1985; 54: 402-408
12. Ardlie NG, McGuiness JA, Garrett JJ: Effect on human platelets of catecholamines at levels achieved in the circulation. Atherosclerosis 1985; 58: 251-259
13. Hjemdahl P, Chronos NA, Wilson DJ, Bouloux P, Goodall AH: Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb 1994; 14: 77-84
14. Goto S, Ikeda Y, Murata M, Handa M, Takahashi E, Yoshioka A, Fujimura Y, Fukuyama M, Handa S, Ogawa S: Epinephrine augments von Willebrand factor-dependent shear-induced platelet aggregation. Circulation 1992; 86: 1859-1863
15. Mustonen P, Lassila R: Epinephrine augments platelet recruitment to immobilized collagen in flowing blood - evidence for a von Willebrand factor-mediated mechanism. Thromb Haemost 1996; 75: 175-181
16. Stump DC, Macfarlane DE: Clonidine and para-aminoclonidine, partial agonists for the α 2 -adrenergic receptor on intact human blood platelets. J Lab Clin Med 1983; 102: 779- 787
17. Banga HS, Simons ER, Brass LF, Rittenhouse SE: Activation of phospholipases A and C in human platelets exposed to epinephrine: role of glycoproteins IIb/IIIa and dual role of epinephrine. Proc Natl Acad Sci USA 1986; 83: 9197-9201
18. Clare KA, Scrutton MC, Thompson NT: Effects of alpha 2-adrenoceptor agonists and of related compounds on aggregation of, and on adenylate cyclase activity in, human platelets. Br J Pharmacol 1984; 82: 467-476
19. Dahmani S, Paris A, Jannier V, Hein L, Rouelle D, Scholz J, Gressens P, Mantz J: Dexmedetomidine increases hippocampal phosphorylated extracellular signal-regulated protein kinase and 2 content by an α 2 -adrenoceptorindependent mechanism: evidence for the involvement of imidazoline I 1 receptors. Anesthesiology 2008; 108: 457-466
20. Ferry N, Henry D, Battais E, Mary A, Bonne C, Hanoune J: Critical assessment of the platelet adenylate cyclase system as a potential model for testing alpha 2 adrenergic activity. Biochem Pharmacol 1986; 35: 1511-1516
21. Michel MC, Regan JW, Gerhardt MA, Neubig RR, Insel PA, Motulsky HJ: Nonadrenergic 3 Hidazoxan binding sites are physically distinct from alpha 2-adrenergic receptors. Mol Pharmacol 1990; 37: 65-68
22. Zonnenchein R, Diamant S, Atlas D: Imidazoline receptors in rat liver cells: a novel receptor or a subtype of alpha 2-adrenoceptors? Eur J Pharmacol 1990; 190: 203-215
23. Piletz JE, Sletten K: Nonadrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther 1993; 267: 1493-1502
24. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther 1996; 279: 694-702
25. Mori K, Kikuchi H, Obara Y, Iwashita M, Azumi Y, Kinugasa S, Inatomi S, Oshima Y, Nakahata N: Inhibitory effect of hericenone B from Hericium erinaceus on collagen-induced plate let aggregation. Phytomedicine 2010; 17: 1082-1085
26. Takano S, Kimura J, Ono T: Inhibition of aggregation of rabbit and human platelets induced by adrenaline and 5-hydroxytryptamine by KB-R7943, a Na + /Ca 2+ exchange inhibitor. Br J Pharmacol 2001; 132: 1383-1388
27. Jackson SP, Nesbitt WS, Kulkarni S: Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1: 1602-1612
28. Varga-Szabo D, Pleines I, Nieswandt B: Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28: 403-412
29. Hikasa Y, Fukui H, Sato Y, Ogasawara S, Matsuda H: Platelet and brain alpha2-adrenoceptors and cardiovascular sensitivity to agonists in dogs suffering from endotoxic shock. Fundam Clin Pharmacol 1998; 12: 498-509
30. Regunathan S, Reis DJ: Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxicol 1996; 36: 511-544
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
32. Hikasa Y, Abe M, Satoh T, Hisashi Y, Ogasawara S, Matsuda H: Effects of imidazoline and non-imidazoline alpha-adrenergic agents on canine platelet aggregation. Pharmacology 1999; 58: 171-182
33. Sweatt JD, Connolly TM, Cragoe EJ, Limbird LE: Evidence that Na+/H+ exchange regulates receptor-mediated phospholipase A2 activation in human platelets. J Biol Chem 1986; 261: 8667-8673
34. Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, Woulfe D, Brass LF: Signaling through Gi family members in platelets: redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem 2002; 277: 46035-46042
35. Mustonen P, van Willigen G, Lassila R: Epinephrine - via activation of p38-MAPK - abolishes the effect of aspirin on platelet deposition to collagen. Thromb Res 2001; 104: 439-449
36. Savi P, Pflieger AM, Herbert JM: cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis 1996; 7: 249-252
37. Weber AA, Hohlfeld T, Schror K: cAMP is an important messenger for ADP-induced platelet aggregation. Platelets 1999; 10: 238-241
38. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP: 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci 1998; 19: 381-390
39. Newman-Tancredi A, Nicolas JP, Audinot V, Gavaudan S, Verriele L, Touzard M, Chaput C, Richard N, Millan MJ: Actions of α2 adrenoceptor ligands at α2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for α2A adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 197-206
40. MacLennan SJ, Luong LA, Jasper JR, To ZP, Eglen RM: Characterization of α 2 -adrenoceptors mediating contraction of dog saphenous vein: identity with the human α 2A subtype. Br J Pharmacol 1997; 121: 1721-1729
41. Pinthong D, Songsermsakul P, Rattanachamnong P, Kendall DA: The effects of imidazoline agents on the aggregation of human platelets. J Pharm Pharmacol 2004; 56: 213- 220
42. Petrusewicz J, Kaliszan R: Effects of imidazoline drugs on human blood platelets aggregation. Thromb Haemost 1985; 54: 784-787
43. Winter JC, Rabin RA: Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J Pharmacol Exp Ther 1992; 263: 682-689
44. Kawai N, Yamamoto T, Baba A, Yamamoto H, Moroji T: Inhibitory effect of idazoxan on forskolin-stimulated adenylate cyclase activity through 5-hydroxytryptamine1A receptors. Arzneimittelforschung 1994; 44: 1-3
45. Sanger DJ, Schoemaker H: Discriminative stimulus properties of 8-OH-DPAT: relationship to affinity for 5HT1A receptors. Psychopharmacology 1992; 108: 85-92
46. Arthur JM, Casanas SJ, Raymond JR: Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Biochem Pharmacol 1993; 45: 2337-2341
47. Murphy TJ, Bylund DB: Oxymetazoline inhibits adenylate cyclase by activation of serotonin-receptors in the OK cell, an established renal epithelial cell line. Mol Pharmacol 1988; 34: 1-7
48. Schoeffter P, Hoyer D: Interaction of the α-adrenoceptor agonist oxymetazoline with serotonin 5-HT 1A, 5-HT 1B, 5-HT 1C and 5-HT 1D receptors. Eur J Pharmacol 1991; 196: 213-216
49. Trincavelli ML, Cuboni S, Montali M, Santaguida S, Lucacchini A, Martini C: Norepinephrine- mediated regulation of 5HT 1 receptor functioning in human platelets. Neurochem Res 2008; 33: 1292-1300